Qingmei He

Qingmei He

Auto-generated profile, based on publicly available information

Qingmei He

Department of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
XHXiaohong Hong
Xiaohong Hong
QLQian Li
Qian Li
JLJunyan Li
Junyan Li
KCKailin Chen
Kailin Chen
QHQingmei He
Qingmei He
YLYingqin Li
Yingqin Li
Purpose: Cisplatin-based chemotherapy effectively improves the distant-metastasis control in nasopharyngeal carcinoma (NPC), but approximately 30% of patients develop treatment failure due to chemoresistance. However, the underlying mechanisms remain poorly understood. Experimental Design: Circular RNA (circRNA) sequencing data were used to identify metastasis-specific circRNAs and the expression of circIPO7 was validated in NPC tissues as well as NPC cell lines by qRT-PCR. The whole transcriptional profile upon circIPO7 knockdown was applied to explore the biological function and regulatory mechanism, which were further confirmed by in vitro and in vivo metastasis/chemosensitivity assays. We also evaluated the value of circIPO7 expression in predicting NPC metastasis and cisplatin chemoresistance by analyzing a cohort of 183 NPC patients. Results: In this study, circIPO7, a novel circRNA, is found to be specifically overexpressed in NPC patients with distant metastasis. Knockdown of circIPO7 in NPC cells suppresses their metastasis and increases sensitivity to cisplatin treatment in vitro and in vivo. Mechanistically, circIPO7 binds to Y-box binding protein-1 (YBX1) protein in the cytoplasm and facilitates its phosphorylation at serine 102 (p-YBX1S102) by the kinase AKT, which further promotes YBX1 nuclear translocation and activates FGFR1, TNC, and NTRK1 transcription. Clinically, higher circIPO7 expression indicates unfavorable distant metastasis-free survival in NPC patients given cisplatin-based chemotherapy. Conclusions: Altogether, this study identifies oncogenic circIPO7 as a prognostic marker after cisplatin-based chemotherapy and as a potential therapeutic target for overcoming metastasis and chemoresistance in NPC.

1 November 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
SLShuman Li
Shuman Li
LJLi Jiang
Li Jiang
QHQingmei He
Qingmei He
WWWeidong Wei
Weidong Wei
YWYun Wang
Yun Wang
DXDan Xie
Dan Xie
Introduction: Primary sarcomatoid carcinoma of the lung (PSC) is a rare subtype of non-small cell lung cancer, which has a bad prognosis and lacks biomarkers for its diagnosis and prognosis. Recent studies suggested that KDM6B (lysine demethylase 6B), also known as Jumonji domain-containing protein D3 (JMJD3), plays an oncogenic role in various human cancers. However, abnormalities of JMJD3 in sarcomatoid carcinoma of the lung and its clinical prognostic significance have not been determined. Therefore, the present study aimed to ascertain the relationship between JMJD3 and PSC. Materials and methods: In this study, immunohistochemistry (IHC) was performed to examine the expression of JMJD3 in a tissue microarray (TMA) containing 96 cases of PSC. Result: Overexpression of JMJD3 was observed in nuclei of the PSC cells. Further analyses indicated that the overexpression of JMJD3 was significantly associated with tumor size, pN stage, and clinical stage. By univariate survival analysis, positive expression of JMJD3 was significantly correlated with shortened patient survival. More importantly, multivariate analysis identified JMJD3 as an independent prognostic factor for sarcomatoid carcinoma of the lung. Conclusion: These findings provide evidence that JMJD3 protein levels, as examined by IHC, may act as a novel prognostic biomarker for patients with primary sarcomatoid carcinoma of the lung.

22 January 2026 in Cancer Research
Verified
Journal Article
Closed access
YZYuheng Zhao
Yuheng Zhao
COChunxian Ou
Chunxian Ou
HHHuimin Huang
Huimin Huang
YWYujue Wang
Yujue Wang
JSJiaxi Shen
Jiaxi Shen
YLYingqin Li
Yingqin Li
Metabolic reprogramming under therapeutic stress may represent a targetable vulnerability for cancer treatment. Elucidation of the metabolic alterations linked to chemotherapy in nasopharyngeal carcinoma (NPC) could uncover potential therapeutic strategies. Using proteomics and transcriptomic profiles, we identified wild-type (WT) isocitrate dehydrogenase 1 (IDH1) as a crucial metabolic enzyme upregulated in gemcitabine plus cisplatin (GP) chemotherapy–resistant NPC. IDH1 reprogrammed nucleotide metabolism in response to chemotherapy, linking DNA damage repair (DDR) to ferroptosis resistance via dihydroorotate dehydrogenase (DHODH), thereby contributing to chemoresistance in NPC. Mechanistically, α-ketoglutarate (αKG), a metabolite of IDH1, enhanced chromatin accessibility to promote DHODH transcription via αKG-dependent dioxygenase AlkB homolog 5 (ALKBH5)–recruited heterogeneous nuclear ribonucleoprotein C (HNRNPC). The DHODH inhibitor BAY2402234 markedly sensitized NPC cells to chemotherapy. Clinically, a prognostic model based on DDR and ferroptosis signatures effectively predicted disease relapse risk following chemotherapy in NPC. This study links DDR to ferroptosis defense via the IDH1/αKG/ALKBH5/DHODH axis, suggesting DHODH inhibition as a promising therapeutic strategy to overcome chemoresistance in tumors harboring WT IDH1. Significance: DHODH-mediated nucleotide metabolic reprogramming represents a targetable vulnerability to counteract chemoresistance in nasopharyngeal carcinoma with wild-type IDH1 overexpression.

26 January 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PZPanpan Zhang
Panpan Zhang
QHQiuping He
Qiuping He
LYLei Yuan
Lei Yuan
YLYingqin Li
Yingqin Li
XWXin Wen
Xin Wen
NLNa Liu
Na Liu

15 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
YLYing-Qi Lu
Ying-Qi Lu
JDJia-Hao Dai
Jia-Hao Dai
YDYu-Fei Duan
Yu-Fei Duan
GQGuan-Jie Qin
Guan-Jie Qin
SHSai-Wei Huang
Sai-Wei Huang
NLNa Liu
Na Liu
The nasopharynx constitutes a critical niche in the upper respiratory tract, harboring a diverse microbiota linked to nasopharyngeal carcinoma (NPC), the mechanistic roles of which remain poorly understood. Here, we established the Nasopharyngeal Mucosal and Tumor-resident Bacterial Catalog (NMTBC) that comprises 5311 bacterial isolates representing 127 species, with 1006 of them being fully sequenced and annotated, providing a comprehensive culturable resource facilitating mechanistic dissection of the microbiome-tumor interactions. With NMTBC, we uncovered a Fusobacterium-Prevotella mutualism and revealed heterotypic bacterium-bacterium interactions involving transcriptional reprogramming and metabolic cross-talk. Using single-bacterial transcriptomics, we mapped a high-resolution transcriptomic trajectory, showing the ability of a single strain to differentiate into functionally distinct subpopulations that cooperate to sustain mutualism. By analyzing a multicenter NPC cohort, we showed that Fusobacterium and Prevotella co-colonization in NPC tumors correlated with unfavorable clinical outcomes after conventional radiochemotherapy. Analysis of RNA-seq data from two previous phase 3 clinical trials showed that coenrichment of Fusobacterium-Prevotella predicted better response to anti-PD-1 immunotherapy, highlighting their important role in microbiota-mediated immunomodulation. Overall, this study establishes a comprehensive nasopharyngeal bacterial catalog through culturomics, which offers valuable insights into microbiome-derived biomarker discovery and immunotherapy patient stratification in clinical practice.

1 January 2021 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
XTXi-Rong Tan
Xi-Rong Tan
SHSheng-Yan Huang
Sheng-Yan Huang
SGSha Gong
Sha Gong
YCYang Chen
Yang Chen
XYXiaojing Yang
Xiaojing Yang
YLYingqing Li
Yingqing Li
Purpose: Serum cystatin C has been considered as a significant prognostic factor for various malignancies. This study aimed to evaluate the relationship between serum cystatin C level before antitumor treatment and the prognosis of nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT). Patients and Methods: A cohort of 2077 NPC patients were enrolled between April 2009 and September 2012. The Kaplan–Meier curves and log rank tests were used to determine the differences of overall survival (OS) and disease-free survival (DFS). Univariate and multivariate Cox regression analyses were used to determine independent prognostic factors. Results: Overall, 362/2077 (17.4%) patients had high serum cystatin C level, and they were older and more male (both P< 0.001), and they had higher TNM stage (all P< 0.05). Kaplan–Meier analysis revealed that patients with high serum cystatin C had worse OS (P< 0.001) and DFS (P< 0.001). Univariate and multivariate Cox regression analysis showed that high serum cystatin C level was an independent prognostic predictor of OS (HR: 1.56, 95%CI: 1.25– 1.95) and DFS (HR: 1.38, 95%CI: 1.13– 1.68). Subgroup analysis based on TNM stage revealed that advanced-stage NPC patients with high serum cystatin C had poorer OS (P< 0.001) and DFS (P< 0.001). Conclusion: Our results revealed that high serum cystatin C level before antitumor treatment can predict clinical outcomes of NPC patients treated with IMRT, and it can guide clinicians to formulate more personalized therapy for NPC patients.